Sirtex Medical (SRX)
Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC. It operates through the following segments: Asia Pacific; Americas; and Europe, Middle East, and Africa. The company was founded in 1997 and is headquartered in North Sydney, Australia.
|Market Price at 18-01-2018
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference Sirtex Medical:
Friday, August 26, 2016
This week many companies released their 2016 reports. We focus in on two big movers. Sirtex Medical gained 12% following a strong result and regained its A1 status. Blackmores fell 23% despite a strong result also retaining its A1 score. Read more to understand why.
Friday, June 05, 2015
At Skaffold’s June webinar, How to invest in top growth stocks, we asked attendees to vote for the stock they wanted Roger Montgomery and Chris Batchelor to discuss. Flight Centre, REA Group and Sirtex Medical topped the list.
Friday, March 20, 2015
Sirtex Medical Limited has been one of the most asked about stocks here at Skaffold, and has been mentioned in a number of webinars and live events, including our most recently held ones. Recently it dropped by 55% in one day after an announcement on SIRFlon clinical results. What happened?
Monday, February 23, 2015
Its one of the most common questions asked by Skaffold members: why does Roger Montgomery buy stocks that are expensive in Skaffold?
At Skaffold’s live event Roger shared a story about McMillan Shakespeare, and explained why he bought Sirtex Medical when Skaffold said it was expensive.
Friday, June 20, 2014
It doesn’t matter if you’re hunting for growth stocks or on the lookout for dividend stocks paying an attractive yield. There are certain characteristics that all stocks should possess before being awarded a place in your share or SMSF portfolio.
At Skaffold’s top growth and yield stocks webinar, stockbroker and market commentator Marcus Padley, together with Skaffold’s Chris Batchelor, reveal how they find top growth and yield stocks to invest in.
Check out this webinar for top-notch insights and a couple of top stocks you may consider adding to your share portfolio.
Friday, June 13, 2014
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.
Tuesday, April 15, 2014
Healthcare represents less than one per cent of the ASX, one of the world’s most dynamic growth sectors.
That’s why most Aussie healthcare stocks trade at what’s known as a ‘scarcity premium’.
Encompassing healthcare facilities, drug and biotechnology stocks, and medical equipment suppliers and manufacturers, the overall quality and performance of Australian healthcare stocks is impressive. Half of the top 10 achieved Skaffold’s preferred stock ratings of A1, A2, B1 and B2 based on their latest financial reports.
Despite a recent sell off, which has seen share prices of the top 10 fall, on average, 3% since late February, safety margins continue to be high, ranging between -15 and -75 per cent.
With the ‘scarcity premium’ enshrouding local healthcare stocks, we went in search of better healthcare value stocks offshore and found 6 standouts.
Thursday, April 10, 2014
How do you find top to stocks to invest in?
David from Victoria shares his investment criteria and the Skaffold filter settings he uses to find top quality companies. David also as gives some background on his investment strategy.
Tuesday, April 01, 2014
Now that the excitement of the reporting season has settled down and analysts have digested financial reports, we take a look inside Skaffold to discover well-positioned, top-quality stocks.
Of the 1767 ASX-listed stocks available for analysis in Skaffold, 163 achieve Skaffold’s preferred scores of A1, A2, B1 and B2. So less than 10 per cent are considered premium investment grade by Skaffold and analysis beyond top-line numbers is critical.
The services sector offers the largest choice of top-quality growth stocks, followed by technology, finance and capital goods.
Thursday, March 13, 2014
With the valuations of ASX-listed companies looking increasingly stretched, it’s more important than ever to use Skaffold’s filters to flag which stocks to avoid in 2014. The filters built into Skaffold stock research software help to remove stocks from your radar that aren’t regarded as investment grade – which by Skaffold’s measure is limited to stocks with an A1, A2 or B1 and B2 rating of balance sheet quality and business performance.
Removing ratings that don’t make the grade culls the stocks you should be seriously looking at down to around 160, which is only 10% of the 1,770 ASX-listed entities rated and evaluated by Skaffold’s automated algorithms.
Remember, even good stocks can and do lose their investment grade status for a myriad reasons, which surface following the release of interim and full year results.